Recurrent Lymphoma Completed Phase 1 Trials for Entinostat (DB11841)

IndicationStatusPhase
DBCOND0073930 (Recurrent Lymphoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02780804Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsTreatment